| Home: Info: News Releases: 2004 Archives: March 23, 2004 |
| Press Release March 23, 2004 | |
LAKE FOREST, Calif. -- (BUSINESS WIRE) -- March 23, 2004-- I-Flow Corporation (Nasdaq:IFLO) today announced that it has filed a preliminary prospectus supplement with the Securities and Exchange Commission relating to a proposed underwritten offering of shares of its common stock. The Company currently plans to offer 2,600,000 newly issued shares and to grant the underwriters a 30-day option to purchase up to an additional 390,000 shares to cover over-allotments, if any. SG Cowen Securities Corporation is acting as the lead manager for the proposed offering. Co-managers of the offering are First Albany Capital Inc., Lazard Freres & Co. LLC, Roth Capital Partners, LLC and Merriman Curhan Ford & Co. A copy of the preliminary prospectus supplement and the accompanying prospectus related to the offering can be obtained when available from SG Cowen Securities Corporation, 1221 Avenue of the Americas, 6th Floor, New York, New York 10020, or through ADP by fax at 631-254-7268. A shelf registration statement relating to the shares that the Company intends to sell has previously been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. I-Flow Corporation designs, develops and markets technically advanced, low-cost drug delivery systems and services that provide life-enhancing, cost-effective solutions for pain relief and intravenous therapy. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from current expectations. The preliminary prospectus supplement and related prospectus contain important information, and potential investors are urged to read these documents and other relevant documents filed by the Company with the Securities and Exchange Commission.
CONTACT: I-Flow Corporation
James R. Talevich, 949-206-2700
www.IFLO.com
or
Berkman Associates
John Hicks (Investor Contact), 310-277-5162
info@BerkmanAssociates.com
SOURCE: I-Flow Corporation
|
JOBS
| NEWS
| SITEMAP | SALES INFOCENTER HEALTHCARE COMPLIANCE PROGRAM | HIPAA PRIVACY NOTICE © 2004-2010 I-FLOW CORPORATION. All Rights Reserved There are inherent risks in all medical devices, please refer to the product labeling for Indications, Cautions, Warnings and Contraindications.For example, failure to follow the product labeling regarding filling, flow rate selection and placement of the pump and/or catheter could directly impact patient safety. Physician is responsible for prescribing and administering medications per instructions provided by the drug manufacturer. |